NEWS

Monoclonal Antibodies - Short Note


Nomenclature of Monoclonal Antibodies.

For nomenclature the name of the MAB can be divided like this

Prefix (variable) --- target --- source ---mab[suffix] (monoclonal antibody)

The following guidelines have been developed for monoclonal antibodies:

1. The suffix -mab is used for monoclonal antibodies and fragments.

2. Identification of the animal source of the product is an important safety factor based on the number of products that may cause source-specific antibodies to develop in patients.
The following letters were approved as product source identifiers:

u
 human
o
 mouse
a
 rat
zu
 humanized
e
 hamster
i
 primate
xi
 chimera
axo
 rat/mouse
xizu
 combination of humanized and chimeric chains

These identifiers are used as infixes preceding the -mab suffix stem, e.g.:

-umab (human)
-omab (mouse)
-ximab (chimera)
-zumab (humanized)

Subclasses



The general disease state subclass must be incorporated into the name by use of a code syllable. The following disease state subclasses were approved based on products currently before the Council. Additional subclasses will be added as necessary.

  • Disease or Target Class:


Old System:



New System:



In order to create a unique name, a distinct, compatible syllable should be selected as the starting prefix.

Sequence of stems: The order for combining the key elements is as follows: Infix representing the target disease state, the source of the product, and the monoclonal root -mab used as a suffix (eg, biciromab, satumomab, nebacumab, sevirumab, tuvirumab). When combining a target or disease infix stem with the source stem for chimeric monoclonal antibody, the last consonant of the target/disease syllable is dropped, eg:

TARGET
SOURCE
-MAB STEM
USAN
-cir-
-xi
-mab
abciximab
-lim-
-zu
-mab
daclizumab

 Few FDA Approved Monoclonal antibodies:


Antibody
Type
Target
Indication
(Targeted disease)
Abciximab (Q)
chimeric
inhibition of glycoprotein IIb/IIIa (Q)
Anti platelet
Adalimumab
human
inhibition of TNF-α signaling (Q)
Several auto-immune disorders
Alemtuzumab
humanized
CD52
Chronic lymphocytic leukemia
Basiliximab
chimeric
IL-2Rα receptor (CD25)
Transplant rejection
Belimumab
human
inihibition of B- cell activating factor
Systemic lupus erythematosus
Bevacizumab (Q)
humanized
Vascular endothelial growth factor (VEGF)
Colorectal cancerAge related macular degeneration (off-label)
Brentuximab vedotin
Chimeric
CD30
Anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma
Canakinumab
Human
IL-1β
Cryopyrin-associated periodic syndrome (CAPS)
Cetuximab (Q)
chimeric
epidermal growth factor receptor
Colorectal cancerHead and neck cancer
Certolizumab pegol
humanized
inhibition of TNF-α signaling
Crohn's disease
Daclizumab
humanized
IL-2Rα receptor (CD25)
Transplant rejection
Denosumab (Q)
Human
RANK Ligand inhibitor (Q)
Postmenopausal osteoporosis , Solid tumor`s bony metasteses
Eculizumab
humanized
Complement system protein C5
Paroxysmal nocturnal hemoglobinuria
Efalizumab
humanized
CD11a
Psoriasis
Gemtuzumab
humanized
CD33
Acute myelogenous leukemia (with calicheamicin)
Golimumab
Human
TNF-alpha inihibitor
Rheumatoid arthritisPsoriatic arthritis, and Ankylosing spondylitis
Ibritumomab tiuxetan
murine
CD20
Non-Hodgkin lymphoma (with yttrium-90 or indium-111)
Infliximab (Q)
chimeric
inhibition of TNF-α signaling
Several autoimmune disorders
Ipilimumab ( MDX-101 )
Human
blocks CTLA-4
Melanoma
Muromonab-CD3
murine
T cell CD3 Receptor
Transplant rejection
Natalizumab
humanized
alpha-4 (α4) integrin,
Multiple sclerosis and Crohn's disease
Ofatumumab
Human
CD20
Chronic lymphocytic leukemia
Omalizumab (Q)
humanized
immunoglobulin E (IgE) (Q)
mainly allergy-related asthma
Palivizumab (Q)
humanized
an epitope of the RSV F protein
Respiratory Syncytial Virus (Q)
Panitumumab
human
epidermal growth factor receptor
Colorectal cancer
Ranibizumab
humanized
Vascular endothelial growth factor A (VEGF-A)
Macular degeneration
Rituximab (Q)
chimeric
CD20
Non-Hodgkin lymphoma
Tocilizumab ( or Atlizumab )
Humanised
Anti- IL-6R
Rheumatoid arthritis
Tositumomab
murine
CD20
Non-Hodgkin lymphoma
Trastuzumab (Q)
humanized
ErbB2 (Q)
Breast cancer (Q)


(Q) - These have been asked in various entrance exams.


References:

1."General policies for monoclonal antibodies" (PDF). World Health Organization. 2009-12-18. Retrieved 2010-06-08.
2. wikipedia.org

Post a comment

Note: only a member of this blog may post a comment.

:ambivalent:
:angry:
:confused:
:content:
:cool:
:crazy:
:cry:
:embarrassed:
:footinmouth:
:frown:
:gasp:
:grin:
:heart:
:hearteyes:
:innocent:
:kiss:
:laughing:
:minifrown:
:minismile:
:moneymouth:
:naughty:
:nerd:
:notamused:
:sarcastic:
:sealed:
:sick:
:slant:
:smile:
:thumbsdown:
:thumbsup:
:wink:
:yuck:
:yum:

Next Post
Newer Post
Previous Post
Older Post